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Epigenetic priming restores the 
HLA class-I antigen processing 
machinery expression in Merkel cell 
carcinoma
Cathrin Ritter1,2,3, Kaiji Fan1,4, Annette Paschen5, Sine Reker Hardrup6, Soldano Ferrone7, 
Paul Nghiem  8, Selma Ugurel5, David Schrama9 & Jürgen C. Becker  1,2,3,5
Merkel cell carcinoma (MCC) is a rare and aggressive, yet highly immunogenic skin cancer. The latter is 
due to its viral or UV-associated carcinogenesis. For tumor progression MCC has to escape the host’s 
immuno-surveillance, e.g. by loss of HLA class-I expression. Indeed, a reduced HLA class-I expression 
was observed in MCC tumor tissues and MCC cell lines. This reduced HLA class-I surface expression 
is caused by an impaired expression of key components of the antigen processing machinery (APM), 
including LMP2 and LMP7 as well as TAP1 and TAP2. Notably, experimental provisions of HLA 
class-I binding peptides restored HLA class-I surface expression on MCC cells. Silencing of the HLA 
class-I APM is due to histone deacetylation as inhibition of histone deacetylases (HDACs) not only 
induced acetylation of histones in the respective promoter regions but also re-expression of APM 
components. Thus, HDAC inhibition restored HLA class-I surface expression in vitro and in a mouse 
xenotransplantation model. In contrast to re-induction of HLA class-I by interferons, HDAC inhibitors 
did not interfere with the expression of immuno-dominant viral proteins. In summary, restoration 
of HLA class-I expression on MCC cells by epigenetic priming is an attractive approach to enhance 
therapies boosting adaptive immune responses.
Merkel cell carcinoma (MCC) is a rare neuroendocrine cancer of the skin, but its incidence has tripled over the 
last 20 years1, 2. Based on the disease-specific mortality rate, it is more lethal than melanoma3. Nevertheless, spon-
taneous remissions of both primary MCC as well as metastatic lesions are frequently reported and explained by 
adaptive immune responses4, 5; thus, MCC appears to be a prime candidate for immunotherapy. Indeed, recent 
clinical trials demonstrated the efficacy of immune checkpoint blocking antibodies6, 7. However, at least half of the 
patients were characterized by a primary resistance to checkpoint blockade, and 14% of the responding patients 
developed secondary resistance at a median follow-up of 33 weeks. Characterization of the mechanisms under-
lying immune-resistant cancer progression may contribute to the rational design of strategies to improve the 
efficacy of immunotherapy in patients suffering from advanced MCC.
The immunogenicity of MCC is based on the association of MCC with a polyomavirus, i.e. the Merkel cell 
polyomavirus (MCPyV) in about 80% of cases8. MCPyV is integrated into the host cell genome, and tumor 
cells critically depend on the expression of the virally encoded large and small T antigen (LT and sT, respec-
tively)9, 10. We previously reported CD8+ T-cell responses targeting LT- and sT-derived epitopes in the majority 
of MCC patients11. Notably, intratumoral infiltration of CD8+ T cells is associated with an improved prognosis12. 
Unfortunately, strong intratumoral CD8+ T-cell infiltration is a sporadic event in MCC, being present in only 
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5% of tumors13. Lack of T-cell infiltration may reflect different immune escape strategies utilized by MCC cells 
such as inhibition of cellular immune responses via PD1/PD-L1 signaling14, 15, and/or defects in classical HLA 
class-I antigen expression16. Reduction of class-I human leukocyte antigens (HLA) surface expression readily 
explains MCC’s resistance to PD-1/PD-L1 blockade, as adaptive T-cell responses critically depend on MHC 
class-I-restricted antigen presentation.
HLA class-I molecules are expressed on the cell surface as heterodimers consisting of the HLA heavy chain 
and the β2-microglobulin (β2m) light chain, stabilized by binding of the presented peptide epitope17. An intri-
cate network of proteases, peptidases, transporters and chaperone molecules, known as the antigen processing 
machinery (APM), is necessary to achieve peptide processing, transportation and loading on HLA class-I mol-
ecules18. Key component of the APM is the proteasome, a multi-protein complex composed of several subunits, 
including the interferon-inducible LMP2 and LMP7 and the transporter complex which is composed of the sub-
units TAP1 and TAP218.
APM component expression in cancer cells is down-regulated often by epigenetic mechanisms and - less fre-
quently - by structural mutations. These epigenetic mechanisms includes promoter methylation and/or histone 
hypoacetylation, and is particularly effective as most APM (LMP2, LMP7, TAP1, TAP2) and classical HLA genes 
(HLA-A, -B and -C) are located in the MHC gene cluster on chromosome 6p19. Herein, we demonstrate epigenetic 
silencing of APM genes in the majority of MCCs in situ and in vitro resulting in markedly reduced classical HLA 
class-I expression. HLA class-I expression, however, can be restored in cell lines as well as in a pre-cinical mouse 
model by pharmacological inhibition of histone deacetylases (HDACs).
Results
MCC is characterized by a reduced HLA class-I expression in situ and in vitro. HLA-A expres-
sion in situ was analyzed by IHC in 56 MCC lesions from 40 patients using an HLA-A specific antibody (clone 
EP1395Y; Fig. 1A). A HLA-A staining score was compiled as described in the material and method section 
(Fig. 1B). In line with Paulson et al.’s observations, 37% (n = 20) MCC lesions entirely lacked HLA-A expression 
(HLA score 0), 37% (n = 21) were characterized by a low expression (HLA score 1–3), 12% (n = 7) by an inter-
mediate expression (HLA score 4–6), whereas only 14% (n = 8) expressed high amounts of HLA-A molecules on 
most of the tumor cells (HLA score 8–12). Next, we analyzed a series of eight MCC cell lines for their HLA class-I 
surface expression with an HLA-A, -B and -C detecting antibody (clone W6/32) by flow cytometry revealing 
differential expression levels of HLA class-I (supplementary Fig. S1). Four MCC cell lines representing almost no 
(MKL-1), low (BroLi), intermediate (WaGa) or high (MKL-2) HLA class-I surface expression were selected for 
further analysis (Fig. 1C). The subcellular localization of HLA-A was determined with an HLA-A detecting anti-
body (clone EP1395Y) by immunofluorescence (Fig. 1D), confirming the respective HLA class-I surface expres-
sion determined by flow cytometry for each cell line. Immunofluorescence also captured that despite reduced 
HLA class-I surface expression of WaGa, BroLi, and MKL-1, HLA-A is still present in their cytoplasm (Fig. 1D).
Reduced HLA class-I cell surface expression on MCC cells is associated with HLA class-I APM 
component down-regulation. To elucidate the mechanism(s) leading to the reduced HLA class-I expres-
sion in MCC, we analyzed gene expression data from 35 cryopreserved MCC tumors, accessible at the gene 
expression omnibus (GEO) database (GSE22396), for HLA-A and B2M. Surprisingly, only ~25% of tumors 
(n = 8) expressed low or intermediate levels of HLA-A mRNA, whereas the majority (~75%, n = 27) contained 
high amounts of HLA-A specific mRNA (Fig. 2A). B2M mRNA was also expressed at intermediate to high levels 
in the majorities of tumors. This discrepancy between HLA-A heavy chain mRNA and HLA-A membrane expres-
sion could be due to a lack of MHC complex stabilization by bound peptides. Thus, we next analyzed the mRNA 
expression of the HLA class-I APM components, TAP1, TAP2, LMP2 and LMP7 in the same data set (GSE22396). 
To this end, TAP1 and TAP2 mRNAs were expressed at very low levels in all analyzed tumors, and LMP2 and 
LMP7 mRNAs at low to intermediate levels in ~75% of tumors (n = 27) (Fig. 2A). To determine whether this 
expression indeed reflect transcript levels in MCC cells and not cells of the tumor microenvironment, we ana-
lyzed the four MCC cell lines with varying degrees of HLA-A surface expression for gene expression of HLA-A, 
B2M, and the APM components. In line with the results generated from the analysis of their expression in tumor 
tissue, HLA-A and B2M mRNAs were present at high levels in all MCC cell lines (Fig. 2B; supplementary Fig. S2), 
irrespective of the MHC class-I membrane expression (Fig. 1C and D). However, the three MCC cell lines with 
reduced MHC class-I membrane expression (BroLi, MKL-1 and WaGa) were characterized by lowered LMP2, 
LMP7, TAP1 and TAP2, mRNA levels (Fig. 2B). Only MKL-2, a cell line showing high MHC class-I expres-
sion, contained high levels of most of the APM- component specific mRNAs (Fig. 2B, supplementary Fig. S2). It 
should be noted, that TAP2 mRNA expression was also low in MKL-2 cells. To confirm this observation at the 
protein level, we performed immunoblots of total cell lysates with HLA-A-, β2m-, TAP1-, TAP2-, LMP2- and 
LMP7-specific mAbs (Fig. 2C), revealing that HLA-A and β2m were expressed in all analyzed MCC cell lines, 
while TAP1 and LMP2, LMP7 expression was largely restricted to the MKL-2 cell line (Fig. 2C). In line with the 
mRNA expression, TAP2 protein was only sparsely expressed in all the analyzed cell lines (Fig. 2C).
External supply of MCPyV-derived peptide epitopes stabilizes HLA class-I surface expression by 
MCC cells. Most MCCs analyzed by us expressed high levels of both HLA heavy and B2M light chain mRNA 
whereas the respective expression of APM components was low. Since empty β2m-HLA class-I heavy chain com-
plexes are rapidly removed from the cell surface and subsequently degraded20, 21, reduced HLA class-I surface 
expression by MCC cells is likely to be due to deficient antigen processing. Indeed, addition of either a pool of 
HLA class-I-restricted T-cell epitopes derived from influenza virus or MCPyV increased the HLA class-I surface 
expression of MKL-1, BroLi and WaGa cell lines (Fig. 2D,E). The used MCPyV peptides have been described 
before11 and were selected according to the HLA-A type of the tested MCC cell line (Supplementary Table S3). 
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In cells with deficient antigen processing such as the TAP-deficient T2 cell line, an excess of externally provided 
peptides binding to the respective HLA molecules stabilizes HLA class-I complexes in an APM-independent 
manner22. Thus, reduced HLA class-I cell surface expression in MCC is at least in part due to a diminished avail-
ability of peptides for HLA class-I stabilization.
Transcription of APM genes in MCC cell lines is epigenetically silenced by histone hypoacetyl-
ation. Expression of APM genes can be silenced by DNA methylation and/or histone hypoacetylation at 
the MHC gene cluster19. Analyses of GSE22396 revealed that a high abundance of histone deacetylase (HDAC) 
mRNAs (sum of HDAC 1–10) was negatively correlated with the mRNAs encoding LMP2, LMP7, TAP1 and 
TAP2, (R squared = 0.32, p = 0.0006; supplementary Fig. S3A). Since no such correlation was observed for meth-
yltransferases (supplementary Fig. S3B), and treatment of MCC cell lines even with high doses (5 µM) of two 
distinct methyltransferase inhibitors (5-azacytidine and RG108) had no effect on HLA class-I surface expression 
(supplementary Fig. S3C), we focused on the relevance of histone hypoacetylation.
Global histone acetylation of MKL-2, WaGa, MKL-1 and BroLi was determined before and after HDAC inhi-
bition by immunoblot (Fig. 3A). As the culture of these MCC cell lines for 24 hours in clinically relevant concen-
trations of vorinostat (V), i.e. the plasma level of 1.25 µM observed under current treatment regimens23, resulted 
only in a modest induction of global histone acetylation, we combined V with mithramycin A (MA). MA is a 
clinically approved DNA-binding cytotoxic antibiotic synergizing with HDAC inhibitors by (i) transcriptionally 
inhibiting the compensatory induction of certain HDACs24 and (ii) by preventing the formation of SP1/HDAC 
inhibitory complexes at the promoters’ GC box25. Notably, the combined treatment of MCC cell lines with V 
Figure 1. HLA class-I expression by MCC tumors in situ and MCC cell lines in vitro. (A,B) 56 MCC tumor 
samples of 40 patients were analyzed by immunohistochemistry for the expression of HLA-A. Samples were 
scored from 0 to 3 for staining intensity and from 0 to 4 for the frequency of positive tumor cells; a combined 
HLA-A expression score was calculated by multiplying both scores. One representative tumor for each HLA 
score group (negative, low, intermediate and high) is depicted in (A); Arrows indicate stromal cells as an 
internal positive control; scale bar represents 100 µm. (C,D) Four MCPyV+ MCC cell lines were analyzed for 
their HLA class-I expression in vitro. (C) HLA class-I surface expression was detected by flow cytometry using 
an HLA-ABC detecting antibody (clone W6/32, blue line); matched isotype controls are depicted as grey filled 
histogram. One representative histogram of triplicates is shown for each cell line. (D) The cellular localization 
of HLA class-I was determined by immune fluorescence using wheat germ agglutinin (Alexa fluor 647, red) 
as membrane marker and a HLA-A detecting antibody (clone EP1395Y) with a dylight 488 labeled secondary 
antibody (green). Representative images for each cell line were captured with a confocal microscope; scale bars 
represent 10 µm.
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and MA resulted in a marked induction of global histone acetylation. Next, histone H3K9 promoter acetylation 
of LMP2, LMP7, TAP1 and TAP2 was analyzed in untreated or V plus MA treated WaGa cells by chromatin 
immune precipitation (ChIP). Treatment with V plus MA increased histone H3K9 acetylation in all analyzed 
promoter regions (Fig. 3B). mRNA expression of APM components LMP2, LMP7, TAP1 and TAP2 was measured 
by RT-qPCR before and after HDAC inhibition in MKL-2, WaGa, MKL-1 and BroLi cells (Fig. 3C). The combined 
treatment with V and MA strongly induced mRNA expression of the analyzed APM component encoding genes 
in all the tested MCC cell lines. As suggested by the increased HLA class-I membrane expression in response 
to the external supply of HLA-binding peptides, HDAC inhibition-induced expression of APM components 
resulted in an increased HLA class-I surface expression as demonstrated by immunofluorescence (Fig. 3D) and 
flow cytometry (Fig. 3E and F). Confocal microscopy also visualized, that HDAC inhibition resulted in a cyto-
plasmic conglomeration of HLA-A protein, most likely in cellular compartments where MHC-class-I complexes 
are assembled, loaded and transported to the cell surface.
Surprisingly, MA treatment alone had a stronger effect on APM gene expression than V alone. However, only 
HDAC inhibition by V plus MA had a marked synergistic effect on HLA class-I surface expression (Fig. 3E and F). 
Figure 2. Reduced HLA class-I expression in MCC is associated with an impaired antigen processing 
machinery (APM). (A) RMA normalized expression values of gene expression array GSE22396, were obtained 
from the GEO database. RMA values were log2 transformed and are depicted as heat map with expression 
values ranging from 7 (blue = low expression) to 14 (red = high expression). HLA-A, B2M, TAP1, TAP2, LMP2 
and LMP7 mRNA expression is shown in comparison to RPLP0. (B) mRNA expression of HLA-A (black), 
B2M (grey), TAP1 (light blue), TAP2 (dark blue), LMP2 (light green) and LMP7 (dark green) in 4 MCC cell 
lines was determined by RT-qPCR in triplicates using specific primers; CT values were normalized to RPLP0 
and calibrated to a set of ΔCTs of MKL-2; relative mRNA expression is depicted as mean + SEM. (C) Protein 
expression in 4 MCC cell lines was determined by immunoblot of whole cell lysates using antibodies specific for 
HLA-A, β2m, TAP1, TAP2, LMP2 and LMP7; β-tubulin served as loading control. (D,E) MCC cell lines with 
low (BroLi, MKL-1) and intermediate (WaGa) HLA class-I surface expression were incubated with saturating 
amounts (10 µM) of a flu peptide mix or MCPyV encoded large and small T antigen and VP1 derived epitopes 
binding with high affinity to the respective HLA-A molecules or an irrelevant peptide cocktail for at least 24 h 
(WaGa and MKL-1) or 48 h (BroLi). HLA class-I surface expression was determined by flow cytometry using an 
HLA-ABC detecting antibody. Induction of HLA class-I surface expression after stabilization with a flu peptide 
mix (green line), exemplarily shown for MKL-1, or the specific MCPyV peptide mix, exemplarily depicted 
for BroLi (blue line). An irrelevant peptide cocktail (grey filled) was used as control (D). Comparison of HLA 
class-I surface expression is depicted as geometric mean fluorescence intensity (gMFI) after incubation with 
MCPyV derived high affinity (blue) or an irrelevant peptide control (grey) for all analyzed MCC cell lines (E).
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 2290  | DOI:10.1038/s41598-017-02608-0
Figure 3. Reduced expression of antigen processing machinery genes is mediated by histone hypoacetylation 
and is increased by pharmacologic histone deactylase inhibition. For all experiments the indicated MCC 
cell lines were analyzed without treatment (grey) and after treatment with mithramycin A (MA, turquoise), 
vorinostat (V, light blue), or the combination thereof (V + MA, dark blue). (A) Global H3K9 acetylation of 
untreated, V, MA or V + MA treated MCC cell lines was determined by immunoblot with an AcH3K9 antibody; 
β-tubulin served as loading control. (B) Chromatin immunoprecipitation (ChIP) assay was performed with 
untreated or V + MA treated WaGa cells followed by a qRT-PCR using TAP1, TAP2, LMP2 or LMP7 promoter 
specific primers. CT values of AcH3K9 antibody or rabbit IgG isotype precipitated DNA were normalized to 
histone H3 antibody precipitated DNA as described in material and methods. Experiments were performed 
in triplicates twice and results are expressed as mean + SEM. (C) mRNA expression of HLA-A, B2M, TAP1, 
TAP2, LMP2 and LMP7 was determined by RT-qPCR in triplicates; CT values were normalized to RPLP0 and 
calibrated to the ΔCT value of untreated MKL-2 cells; relative mRNA expression is depicted + SEM for MKL-2, 
BroLi, MKL-1 and WaGa. (D) HLA class-I intracellular localization was determined via immunofluorescent 
staining using an HLA-A detecting antibody (clone EP1395Y) with a dylight 488 labeled secondary antibody 
(green). Wheat germ agglutinin (Alexa fluor 647, red) was used to stain cellular membranes and DAPI (blue) 
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It is important to note, that the combined treatment did not interfere with the expression of MCPyV-encoded 
proteins, which represent the source of immunogenic epitopes in MCPyV+ MCC (Fig. 3G).
HDAC inhibition induces histone acetylation and HLA class-I stabilization in vivo. Next, we 
translated these observations into a MCC xenotransplantation model based on WaGa cells and NOD/SCID 
mice26. Once the induced tumors reached a volume of approximately 100 mm3, treatment with i.p. injections of 
either V plus MA or the respective drug carriers was started. Mice were treated for two weeks at concentrations 
equivalent to those applied in humans. Forty-eight hours after the last dosage, animals were sacrificed and tum-
ors harvested. In analogy to the in vitro results, treatment of mice with V plus MA significantly increased the 
transcription of TAP2, LMP2 and LMP7 in xenotransplanted MCC tumors (p < 0.05; Fig. 4A). However, the 
expression of TAP1 in vivo was not increased by this treatment; this finding may reflect the strong TAP1 induc-
tion by xenotransplantation itself. This induction may be due to the fact that NOD/SCID mice are comprised of 
functional B and T cells, but still harbor functional dendritic cells and NK cells expressing interferon gamma27. 
Immunohistochemistry of the xenotransplants confirmed that these effects were indeed due to HDAC inhibition, 
as histone H3K9 acetylation was strongly induced by treatment of mice with V plus MA (Fig. 4B). Consequently, 
the combined treatment enhanced the HLA class-I surface expression on WaGa xenotransplants (Fig. 4B). In 
accordance to the in vitro results RT-qPCR did not demonstrate any increase in HLA-A and β2m mRNA expres-
sion in response to treatment with V plus MA, supporting the assumption that HDAC inhibitor mediated HLA 
class-I induction on MCC cells is largely mediated by an enhanced antigen processing (Fig. 4A). Furthermore, it 
is important to note that MCPyV large T antigen (LT) protein expression was not altered in MCC xenotransplants 
by V plus MA treatment (Fig. 4B).
Discussion
Virus-associated malignancies like MCC are highly immunogenic and are consequently subjected to a strong 
immuno-selective pressure. Thus, these cancers can only progress if efficient immune escape strategies are oper-
ative. Indeed, although most patients harbor MCPyV-derived epitope-specific CD8+ T cells circulating in the 
blood11, 28, and that in most MCC cases the oncogenic phenotype critically depends on continuous expression of 
the MCPyV early genes9, 10, brisk T-cell infiltrates in MCC tumors are rare13, 29.
Consequently, immune modulation is a promising therapeutic option for MCC patients, which is currently 
tested in several clinical trials including: autologous MCPyV-specific CD8+ T-cell transfer, checkpoint blocking 
antibodies, or cytokine-based therapies using tumor stroma-targeting antibody-IL2 fusion proteins and in vivo 
electroporation of IL-2-coding plasmids (reviewed in ref. 30). Notably, very promising results on the efficacy of 
immune checkpoint blocking antibodies have already been reported6, 7. These therapeutic approaches depend 
on MCC-specific adaptive immune responses. For cytotoxic T cells a cognate recognition, i.e. interaction of the 
T-cell receptor with suiTab. peptide/HLA class-I complexes presented on the surface of the target cells, is essen-
tial. Thus, it is not surprising that diminished HLA class-I expression on cancer cells is one of the major immune 
escape mechanisms both spontaneously and in response to immunotherapy31–34. The molecular mechanisms to 
achieve such an HLA class-I loss are multiple and vary depending both on the type of tumor as well as on the 
individual patient35.
In line with recent reports, we demonstrate here that the impaired HLA class-I expression is a frequent 
immune escape mechanism of MCC, which however, appears not to be genetically fixed as it can be therapeu-
tically overcome16. Actually, we demonstrate here that the common underlying molecular mechanism of HLA 
class-I loss observed in the MCC cell lines investigated by us is epigenetic silencing of the antigen presentation 
machinery (APM): The transporter subunits TAP1 and TAP2 as well as the immunoproteasome subunits LMP2 
and LMP7 are simultaneously down-regulated by histone hypoacetylation. While genetic aberrations in single 
components of the APM have been reported18, the synchronized down-regulation of several APM components 
appears to be an even more efficient immune escape mechanism36.
Viral infection of cells is frequently associated with an inflammatory response. Thus, infected cells are exposed 
to cytokines such as interferon gamma, which results in the replacement of certain catalytic subunits of the pro-
teasome by LMP2 and LMP7 to allow the formation of the immunoproteasome37. The immunoproteasome not 
only generates a broader spectrum of peptides for presentation by HLA class-I complexes, but is also much more 
efficient in processing viral proteins, which are poorly processed by the regular proteasome38, 39. Thus, epigenetic 
silencing of LMP2 and LMP7 is a particularly suiTab. means of immune evasion for cancers with a viral car-
cinogenesis such as MCC. Indeed, viruses can change the host epigenome in order to escape immune responses 
(reviewed in ref. 40). In this regard, viral infection can alter the host epigenome directly via the interaction of viral 
components with the epigenetic machinery of the infected cell41, 42, or indirectly due to the increased immune 
selective pressure caused by the expression of viral antigens. It has to be elucidated which scenario is operative 
in MCC.
served as nuclear stain. Single cell images in the upper right corner of the overview image were acquired using 
confocal microscopy. (E,F) HLA class-I cell surface expression was determined by flow cytometry using a 
HLA-ABC specific antibody as exemplified for WaGa (E); the results for all cell lines analyzed are depicted 
as the geometric mean fluorescence intensity (gMFI) of HLA class-I (HLA-ABC) staining, + SEM in three 
independent experiments (F). Statistical analysis was performed using the Friedman test as indicated. (G) Viral 
protein expression was determined by immunoblot of whole cell lysates using an antibody specific for LT (clone 
CM2B4) depicting the different truncated LTs characteristically for MCC cells. β-tubulin served as loading 
control.
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Figure 4. Histone deactylase inhibition induces histone H3K9 acetylation and HLA class-I expression and 
does not reduce LT expression in vivo. NOD.CB17/Prkdcscid mice (n = 5 for each treatment group) bearing 
xenotransplanted WaGa tumors were treated with the drug carrier polyethylene glycol (control, grey), or the 
combination of vorinostat and mithramycin A (V + MA, dark blue) as described in materials and methods. (A) 
mRNA was isolated from cryopreserved tumors and RT-qPCR was performed using primers for HLA-A, B2M, 
TAP1, TAP2, LMP2 and LMP7. CT values were normalized to RPLP0 and calibrated to in vitro cultured WaGa 
cells. (B) Immunohistochemistry was performed on sections of FFPE fixed tumors using antibodies specific 
against AcH3K9, LT (clone CM2B4) and HLA-A. A representative example for each group is depicted. Scale 
bars represent 100 µm.
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In any case, this highly effective immune escape mechanism may be reversed pharmacologically: 
Epigenetically silenced genes of the HLA class-I locus are effectively re-induced by HDAC inhibition43–45. To 
this end, treatment of MCC cells with the HDAC inhibitor vorinostat in combination with the Sp1 inhibitor 
mithramycin A resulted in the transcription of the APM components followed by HLA class-I surface expression. 
Notably, we observed this effect at clinically relevant concentrations and could translate these findings into a 
pre-clinical in vivo model. Consequently, epigenetic immunological priming could be readily used to overcome 
primary or secondary resistance to PD-1/PD-L1 blocking antibodies6, 7. Indeed, the combination of different 
HDAC inhibitors with immune checkpoint blocking antibodies is currently tested in solid tumors, including mel-
anoma and non-small cell lung cancer (Supplementary Table S4). This notion is particularly attractive for MCC, 
since HDAC inhibition also induces the expression of activating and co-activating molecules such as NKG2D 
ligands46. An alternative means to up-regulate HLA class-I surface expression are interferons. We have previously 
reported that both type I and II interferons are potent inducers of HLA class-I surface expression in MCC11, 16. 
However, interferons reduce the expression of the MCPyV encoded sT and LT transforming early genes26, i.e. the 
source which most of the immuno-dominant T cell epitopes are derived from11. In line with this, treatment of 
two MCC patients with MCPyV positive primary tumors and metastasis with interferon alpha had no therapeutic 
effect47.
We here demonstrate that epigenetic priming by HDAC inhibition appears to be an effective means to improve 
viral antigen processing and surface presentation in the majority of MCCs. MCC patients characterized by pri-
mary or secondary resistance to immunotherapy are likely to be rendered responsive by HDAC inhibition. As 
demonstrated here, testing for HLA class-I expression together with the H3K9 acetylation status of tumor lesions 
by immunohistochemistry, which can be readily performed in FFPE samples, may prove to be a valuable predic-
tive biomarker of response to immunotherapy48–50. As mentioned above, there are currently several clinical trials 
ongoing in which the combination of HDAC inhibition and immunotherapy is tested as treatment of solid tumors 
(Supplementary Table S4); based on the presented data, MCC should be one of these cancers.
Material and Methods
MCC tumor samples. A total of 56 formalin-fixed and paraffin-embedded (FFPE) tumor samples from 40 
unselected MCC patients presenting at the Department of Dermatology, Medical University of Graz, were used 
for analysis. All tumor samples were excised for diagnostic or therapeutic reasons between 1992 and 2013, and 
were confirmed to be Merkel cell carcinoma according to established histological and immunohistochemical 
diagnostic guidelines. FFPE specimens included primary lesions, recurrent tumors, as well as metastases to the 
skin or lymph nodes. All studies on human material were approved by the institutional review board of the 
Medical University of Graz (24–295 ex 11/12). Informed consent has been obtained and the methods were carried 
out in accordance with the approved guidelines.
Immunohistochemistry. Immunohistochemistry (IHC) was performed on FFPE tissue as describe 
before47. In short antigens were retrieved using a citrate buffer (Retrieval solution, cat. no. S1699, pH 6, 
Dako, Glostrup, Denmark) in a steamer at 100 °C for 30 minutes. Antibodies used in this study are listed in 
Supplementary Table S1. Samples were incubated for 1 hour with an HLA-A specific antibody (clone EP1395Y, 
Abcam, Bristol, UK) diluted 1:1000 in antibody diluent (Dako). After incubation with a biotinylated second-
ary antibody and addition of streptavidin peroxidase, the detection was obtained using ImmPACT NovaRED 
Peroxidase Substrate (Vector Laboratories, Burlingame, CA, USA). Three independent investigators (CR, DS, 
JCB) classified the staining intensity on a scale from zero to three and the percentage of HLA-A positive cells as 
follows: 0% = 0, 1–25% = 1, 26–50% = 2, 51–75% = 3, >75% = 4. The HLA-A staining score was calculated by 
multiplying the score for staining intensity with the percentage of positive cells (min = 0, max = 12).
Cell culture. The classical MCPyV+ MCC cell lines BroLi, MKL-1, MKL-2, and WaGa have been described 
before51. All cell lines were authenticated by STR analysis on regular bases (last performed in June 2016). Cell lines 
were maintained in RPMI-1640 (PAN Biotech, Aidenbach, Germany) supplemented with 10% fetal bovine serum 
(FBS; Biochrom, Berlin, Germany) and 1% penicillin/streptomycin (Biochrome, Berlin, Germany). For treatment 
with specific inhibitors, cells were cultured at a concentration of 1 × 106 cells/ml in 6-well plates. Inhibitors were 
dissolved according to the manufacturers’ guidelines and used at 1.25 µM for vorinostat (Selleckchem, Munich, 
Germany), 0.3 µM for mithramycin A (Sigma, St. Louis, MO, USA), 5 µM for RG108 and 5 µM 5-azacytidine 
(Selleckchem) for 24 h if not otherwise stated.
Flow cytometry. Cell surface expression of HLA class-I was determined by flow cytometry. 1 × 106 cells were 
incubated with an FITC conjugated anti-HLA-ABC antibody (Supplementary Table S1, clone W6/32, BioLegend, 
San Diego, CA, USA) in PBS supplemented with 0.1% bovine serum albumin (BSA) for 90 minutes at 4 °C in the 
dark. After washing, cells were stained with 10 µg/ml 7-aminoactinomycin (7AAD, Sigma) for viable/non-viable 
discrimination, and measured on a FC500 Flow Cytometer (Beckman Coulter, Brea, CA, USA). Data were ana-
lyzed with FlowJo Version 8.7 software (TreeStar, Sunnyvale, CA, USA).
Immunofluorescence. Before immunofluorescence staining, MCC cells were attached to coverslips by 
poly-L-lysine coating. In short, coverslips were coated with 0.01% of poly-L-lysin (Sigma) for 10 minutes, and 
placed after one wash with PBS in a 12-well plate. 1 ml of cell suspension was added per well and incubated for 
30 minutes at 37 °C in 5% CO2. After excess media was removed, the cells were washed with PBS once and incu-
bated with 5 µg/ml wheat germ agglutinin (WGA, conjugated with Alexa Fluor 647) for 30 minutes at room tem-
perature to stain cellular membranes. After three 5 minute washing steps with PBS, cells were fixed with ice cold 
acetone for 10 minutes, followed by three more washes with PBS and blocking with 1% bovine serum albumin 
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(BSA) in PBS for one hour. Samples then were incubated with an antibody specific for HLA-A (Supplementary 
Table S1, clone EP1395Y, Abcam) diluted 1:250 in blocking solution over night at 4 °C. After three washes with 
PBS a dylight 488 conjugated goat-anti-rabbit IgG (Thermo Scientific, Waltham, MA, USA) was added at a 1:200 
dilution in blocking reagent for 1 hour at room temperature. Cells were washed three more times and nuclei were 
stained with DAPI. Cells were washed with PBS three more times and embedded with ProLong Dimond Antifade 
Mountant (Invitrogen, Carlsbad, CA, USA) and incubated at room temperature in the dark for 24 h before imag-
ing. For spheroid imaging a Zeiss Axio Observer.Z1 with Apotome.2 system was used. Subcellular imaging of 
individual cells was performed with a Leica SP5 inverse confocal laser scanning microscope.
Quantitative real time polymerase chain reactions. mRNA of in vitro propagated cells or cryopre-
served xenografts was isolated, transcribed into cDNA and RT-qPCR was performed as described before46. RPLP0 
served as endogenous control using specific primers and Taqman probe, listed in Supplementary Table S2. The 
mRNA expression of HLA-A, B2M, TAP1, TAP2, LMP2, LMP7 was detected using SYBR green assays with spe-
cific primers listed in Supplementary Table S2. Relative quantification was calculated by the ΔΔCt method.
Immunoblot. Cell lysates were generated by exposing 3 × 106 cells to protein extraction buffer supplemented 
with a proteinase inhibitor cocktail as described before52. Lysates were subjected to sodium dodecyl sulfate pol-
yacrylamide gel electrophoresis (SDS-Page), subsequently transferred to a nitrocellulose membrane (Bio-Rad, 
Hercules, CA, USA), incubated first for 1 hour in blocking buffer, and then overnight at 4 °C with the respective 
primary antibodies (Supplementary Table S1) in predetermined dilutions in phosphate buffered saline (PBS) 
supplemented with 0.1% Tween 20 (PBST): anti-HLA-A (clone EP1395Y, Abcam, 1:4000), anti-β-Tubulin 
(clone TUB2.1, Sigma, 1:200), anti-B2M (1:500), anti-TAP1(1:500), anti-TAP2(1:500), anti-LMP2 (1:500) and 
anti-LMP7 (1:500); antibodies against B2M, TAP1, TAP2, LMP2 and LMP7, that are not commercially available 
have been described before53. Global histone acetylation was determined using an anti-acetyl-H3K9 (AcH3K9) 
antibody (Cell Signaling, Cambridge, UK, clone C5B11, 1:500). MCPyV LT antigen was detected using the anti-
body clone CM2B4 (Santa Cruz, Dallas, TX, USA, 1:250). The next day, membranes were washed and incubated 
for 1 hour with the appropriate peroxidase-coupled secondary antibodies (Dako), followed by visualization using 
the ECL Western Blotting Substrate (Pierce, Waltham, MA, USA).
HLA class-I stabilization assay. MCC cell lines were incubated with 10 µM of a flu-peptide-pool 
(PANATecs, Heilbronn, Germany) or a peptide mixture of MCPyV LT-, sT- and VP1-derived epitopes known to 
match the respective HLA types of the used cell lines (Supplementary Table S3)11. The flu-peptide-pool served as a 
well established positive control for HLA class-I stabilization54. As negative control, an irrelevant peptide with no 
HLA binding motif was used. Incubation was performed until optimal HLA class-I stabilization was observed, i.e. 
24 hours for WaGa and MKL-1 and 48 hours for BroLi. Quantification of HLA class-I expression by flow cytom-
etry was performed as described above.
Chromatin immune precipitation (ChIP). ChIP assays were performed using the SimpleChiP® 
Enzymatic Chromatin IP Kit with agarose beads (Cell Signaling). In brief, proteins were cross-linked to DNA 
with 1.5% formaldehyde for 10 minutes. Nuclear membranes were broken up using the Bioruptor sonicator 
(Diagenode, Seraing, Belgium) set to high, for 2 cycles of 10 minutes (30 seconds on/30 seconds off). Afterwards, 
antibodies against histone H3 (clone D2B12, Cell Signaling), acetyl-histone H3 (Lys9) (AcH3K9) (clone C5B11, 
Cell Signaling), or normal rabbit IgG (cat. no. 2729, Cell Signaling) were used for immune precipitation. The pre-
cipitated DNA was analyzed by qRT-PCR using primers specific for the TAP1, TAP2, LMP2 (PSMB9) or LMP7 
(PSMB8) promoter region; primer sequences are given in Supplementary Table S2. The percentage of acetylated 
histones H3 (AcH3K9) was normalized to total histones H3 and calculated using following equation:
= ∗ − .%AcH3 over total H3 100 2(C H3 C AcH3K9)T T
Xenotransplantation experiments. Six-week-old female NOD.CB17/Prkdcscid mice were obtained from 
Charles River Laboratories (Erkrath, Germany) and housed under specific pathogen-free conditions. Tumors 
were induced by s.c. injection as described before26. Twenty-four days after tumor cell inoculation at a vol-
ume of approximately 100 mm3 treatment was started. Mice were divided into four groups of five ensuring an 
equal overall tumor burden. Mice were treated with 60 mg/kg vorinostat in combination with 0.2 mg/kg bod-
yweight or the drug carrier 45% Polyethylene glycol (PEG-400, Sigma) intra-peritoneal injection as describe 
befor46. Mice were treated five consecutive days per week for two weeks. IHC was performed as described in 
the Immunohistochemistry section. Anti-acetyl-histone H3 (Lys9) (AcH3K9) (cell signaling, cat. no. 9671) was 
diluted 1:50 and the LT specific antibody clone CM2B4 was diluted 1:200 (Supplementary Table S1). All animal 
studies were approved by the Austrian ministry of education and science according to the regulations for animal 
experimentation (BMWF-66.010/0151-II/3b/2012).
Statistics. Statistical analyses were performed using Graphpad Prism 6.0 Software (Graphpad Software Inc., 
San Diego, CA, USA). Cell culture experiments were analyzed using Friedman test, a paired non-parametric 
ANOVA. A p-value smaller than 0.05 was considered significant and indicated by * in the figures.
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